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The molecular mechanisms of toxicity and cellular transport of anticancer metallodrugs,
including platinum-based agents, have not yet been fully elucidated. The aim of our study
was to investigate the relevance of copper transporters (CTR1 and ATP7A/B), organic
cation transporters (OCT2) and the multidrug and toxin extrusion proteins (MATE) in
the intracellular accumulation of a novel organometallic cytotoxic Au(III) compound in
cancer cells in comparison to cisplatin. Specifically, the synthesis and characterization of
the gold complex [Au(pyb-H)(PPh2Ar)Cl]PF6 (PPh2Ar= 3-[4-(diphenylphosphino)phenyl]-
7-methoxy-2H-chromen-2-one] (1), featuring a coumarin ligand endowed with “smart”
fluorescence properties, have been achieved. Initially, the cytotoxic effects of both
cisplatin and 1 were studied in a small panel of human cancer cells, and against a
non-tumorigenic cell line in vitro. Thus, the human ovarian cancer cell line A2780 and
its cisplatin resistant variant A2780cisR, were selected, being most sensitive to the
treatment of the gold complex. Co-incubation of the metallodrugs with CuCl2 (a CTR1
substrate) increased the cytotoxic effects of both the Au(III) complex and cisplatin;
while co-incubation with cimetidine (inhibitor of OCT2 and MATE) showed some effect
only after 72 h incubation. ICP-MS (Inductively Coupled Plasma Mass Spectrometry)
analysis of the cell extracts showed that co-incubation with CuCl2 increases Au and Cu
accumulation in both cancer cell lines, in accordance with the enhanced antiproliferative
effects. Conversely, for cisplatin, no increase in Pt content could be observed in both
cell lines after co-incubation with either CuCl2 or cimetidine, excluding the involvement
of CTR1, OCT2, and MATE in drug accumulation and overall anticancer effects. This
result, together with the evidence for increased Cu content in A2780 cells after cisplatin
co-treatment with CuCl2, suggests that copper accumulation is the reason for the
observed enhanced anticancer effects in this cell line. Moreover, metal uptake studies
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in the same cell lines indicate that both 1 and cisplatin are not transported intracellularly
by CTR1 and OCT2. Finally, preliminary fluorescence microscopy studies enabled the
visualization of the sub-cellular distribution of the gold compound in A2780 cells,
suggesting accumulation in specific cytosolic components/organelles.
Keywords: organometallic gold compounds, cisplatin, cancer, drug transporters, organic cation transporters,
copper transporters, ICP-MS
INTRODUCTION
In the field of anticancer metallodrugs, platinum(II)
compounds (cisplatin (Figure 1), carboplatin, oxaliplatin,
and nedaplatin) are still the gold-standard treatment for
numerous types of cancers,(Desoize and Madoulet, 2002) mostly
applied in combination with other chemotherapeutics. However,
their use is limited due to intrinsic or acquired resistance and
severe side-effects, such as nephrotoxicity in the case of cisplatin.
Consequently, a panel of non-platinum metallodrugs was
designed as anticancer agents to achieve improved therapeutics.
Many of them are in preclinical studies, but only a few reached
clinical trials and are still far from being marketed (Ang et al.,
2011; Jaouen et al., 2015; Meier-Menches et al., 2018). In general,
the differential activity/toxicity profiles of anticancer drugs in
different organs, such as the nephrotoxicity of cisplatin, may
be related to different drug accumulation in the cells of these
tissues. It is worth mentioning that higher drug accumulation
in a particular cell type might be caused by either higher
uptake or lower eﬄux(Fletcher et al., 2010; Russel, 2010), which
emphasizes the need for mechanistic information on the drug
transport mechanisms involved and possible interactions with
membrane transporters. However, even for the well-established
anticancer platinum drugs, knowledge about their mechanism
of accumulation in cancer cells, as well as in healthy tissues, is
incomplete and often contradictory. Specifically, the hOCT2
(human organic cation transporter 2) and hCTR1 (human
copper transporter 1) have been postulated to be involved in the
uptake of cisplatin, whereas the multidrug and toxic extrusion
protein (MATE) and ATP7A/B seem to be involved in the drug’s
eﬄux, as recently reviewed by Spreckelmeyer et al. (2014) and
others (Hall et al., 2008; Howell et al., 2010). It should be noted
that while hCTR1 is responsible for the cellular uptake of Cu+
ions, the ATP7A and ATP7B are pumps known to be involved in
the eﬄux of copper ions. MATEs are part of the organic cation
homeostasis, belonging to the SLC47 family. In fact, MATEs act
as H+/organic cation antiporters, transporting protons from
the extracellular side to the cytoplasm in concomitance with
organic cations export to the lumen of the proximal tubule.
Several studies have confirmed cisplatin transport by MATEs
(Ciarimboli, 2014).
Recently, Natile, Arnesano, and co-workers investigated the
binding of platinum(II) complexes to the Met-rich domain
of hCTR1 by several methods including mass spectrometry
and NMR spectroscopy (Arnesano et al., 2007; Alessia et al.,
2018). According to the obtained results, cisplatin reacts with
the copper binding domain forming adducts where all the
original ligands of Pt(II) are substituted by the S-donor groups
of Met side-chains. According to these observations, cisplatin
would be actually sequestered by hCTR1 and not transported
intracellularly. Furthermore, regulation of the expression of these
membrane transporters upon metallodrug administration can
also occur and its effects on cisplatin treatment should be
considered (Holzer and Howell, 2006). Recently, Howell and
coworkers reported on the use of the CRISPR-Cas9 technique
to individually knock out the human copper transporters CTR1
andCTR2 and the copper chaperones ATOX1 andCCS in human
cancer cells (Bompiani et al., 2016). The obtained results showed
that loss of such transporters does not produce a change in
cisplatin sensitivity.
Among new generation metal-based complexes, gold(I)
and gold(III) compounds raised interest in the last years
showing promising anticancer properties in vitro, which
prompted the investigation of their molecular mechanisms
of biological action (Ott, 2009; Bertrand and Casini,
2014). As a representative example, the gold(I) compound
auranofin ([Au(I)(2,3,4,6-tetra-O-acetyl-1-(thio-κS)-β-D-
glucopyranosato)(triethylphosphine)]) is a potent cytotoxic
agent in vitro and is currently in clinical trials (Nobili et al., 2010).
Among the various families of gold compounds tested for their
anticancer effects in the last decade, a variety of organometallic
gold(I/III) compounds appeared to be particularly promising
(Muenzner et al., 2015; Sigel et al., 2018). Indeed, they feature
potent anticancer activity in vitro, and are endowed with
improved stability in physiological environment with respect to
classical coordination complexes. In this context, our group has
designed new gold(III) cyclometallated compounds featuring
both bidentate C∧N- and tridentate C∧N∧N-, C∧N∧C-, and
N∧C∧N-donor ligands, with either five- or six-membered C,N
rings.(Bertrand and Casini, 2014; Fung et al., 2017; Jurgens
and Casini, 2017; Jurgens et al., 2017a; Jürgens et al., 2017b;
Williams et al., 2017; Bertrand et al., 2018) For example, a series
of C∧N gold(III) complexes of general formula [Au(pyb-H)X2]
(pyb-H = C∧N cyclometallated 2-benzylpyridine) has been
developed by us showing interesting antiproliferative effects in a
panel of human cancer cells in vitro (Bertrand et al., 2015).
While investigation of the possible pharmacological targets for
this family of organometallic gold(III) complexes has led to the
identification of a number of cancer-related proteins, including
the seleno-enzyme thioredoxin reductase, (Gabbiani et al., 2011)
and zinc finger proteins involved in DNA repair mechanisms,
(Wenzel et al., 2018) among others, very scarce information is
available concerning the drug transport mechanisms in cancer
cells. As far as we are aware, only one in vitro study has
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been published evaluating the role of hOCTs, hCTR1, and of
endocytotic processes in the uptake of a cytotoxic gold(I) NHC
(N-heterocyclic carbene) complex in cancer cells (Kaps et al.,
2012). The results suggest that cellular uptake for all tested gold
complexes occurs mainly via the OCT transporters, but in one
case also via hCTR1. In addition, some of the compounds were
also internalized via the Na+/K+-dependent endocytosis (Kaps
et al., 2012). In fact, while in general endocytosis is the vesicle-
mediated process used by all cells to internalize extracellular
molecules, some endocytotic processes depend on a sodium
gradient and can be slowed down by adding ouabaine, an
inhibitor of the Na+/K+ pump.
More recently, we reported on the toxic effects and
accumulation mechanisms of another C∧N gold(III) complex–
[Au(pyb-H)(PTA)Cl] (PTA = 1,3,5-triazaphosphaadamantane)
(Figure 1)–in healthy rat kidneys ex vivo, using the Precision
Cut Tissue Slices (PCTS) method (Spreckelmeyer et al., 2017).
Interestingly, the obtained results seem to exclude OCTs-related
FIGURE 1 | The anticancer Pt(II) drug, cisplatin, and cyclometallated
[Au(pyb-H)PTACl] (pyb-H = C∧N cyclometallated 2-benzylpyridine,
PTA = 1,3,5-triazaphosphaadamantane).
uptake mechanisms as well as MATE eﬄux pathways for this
gold(III) compound in kidneys.
Here, we report on the synthesis and characterization
of a novel cyclometallated C∧N gold(III) compound
(Figure 2) [Au(pyb-H)(PPh2Ar)Cl]PF6 (PPh2Ar = 3-[4-
(diphenylphosphino)phenyl]-7-methoxy-2H-chromen-2-one]
(1) featuring a coumarin ligand endowed with “smart”
fluorescence properties for imaging in cells by fluorescence
microscopy (Hanthorn et al., 2012; Ali et al., 2015; Dondaine
et al., 2016). The smart character of this probe involves a
dramatic drop of the fluorescence when the metal is released,
allowing a reliable tracking of the complex: if strong fluorescence
is observed it means that the “P-Au” bond is intact. The
evaluation of the antiproliferative effects of the Au(III) complex
compared to cisplatin was performed using a panel of human
cancer cell lines as well as non-cancerous cells in vitro. Moreover,
the involvement of different transporters (CTR1, OCT2,
MATE, ATP7A/B) in the antiproliferative activity of the gold
compound was studied via transporter inhibition experiments in
comparison to cisplatin in two human ovarian cancer cell lines,
one sensitive (A2780) and one resistant to cisplatin (A2780cisR).
Furthermore, the accumulation and uptake mechanisms of
the compounds were studied in the same cells, evaluating the
cellular metal content by Inductively Coupled Plasma Mass
Spectrometry (ICP-MS). Preliminary fluorescence microscopy
data allowed investigation of the sub-cellular localization of
complex 1 in cancer cells.
MATERIALS AND METHODS
General Remarks
All reactions were carried out under an atmosphere of purified
argon using Schlenk techniques. Solvents were dried and distilled
under argon before use. Cisplatin was purchased at Sigma, while
the precursor [Au(pyb-H)Cl2] and the coumarin-phosphine have
been synthesized according to literature procedure (Cinellu et al.,
1995; Hanthorn et al., 2012). The identity and purity (≥95%)
FIGURE 2 | Synthesis of compound [Au(pyb-H)(PPh2Ar)Cl]PF6 (PPh2Ar = 3-[4 (diphenylphosphino)phenyl]-7-methoxy-2H-chromen-2-one] 1.
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of the gold complexes under investigation were unambiguously
established using high-resolution mass spectrometry and NMR.
All other reagents were commercially available and used as
received. All the analyses were performed at the “Plateforme
d’Analyses Chimiques et de Synthèse Moléculaire de l’Université
de Bourgogne.” Exact masses of the synthesized complexes
were obtained on a Thermo LTQ Orbitrap XL. 1H- (300.13,
500.13, or 600.23 MHz), 13C- (125.77 or 150.90 MHz) and 31P-
(121.49, 202.45, or 242.94 MHz) NMR spectra were recorded
on Bruker 300 Avance III, 500 Avance III or 600 Avance II
spectrometers. Chemical shifts are quoted in ppm (δ) relative
to TMS (1H and 13C) using the residual protonated solvent
(1H) or the deuterated solvent (13C) as internal standards. 85%
H3PO4 (
31P) was used as an external standard. Infrared spectra
were recorded on a Bruker Vector 22 FT-IR spectrophotometer
(Golden Gate ATR) and far infrared spectra were recorded
on a Bruker Vertex 70v FT-IR spectrophotometer (Diamant
ATR).
Synthesis of [Au(pyb-H)(PPh2Ar)Cl].PF6 (1)
A round-bottom flask was charged with the precursor [Au(pyb-
H)Cl2] (50mg, 0.115 mmol, 1 eq.), KPF6 (106mg, 0.573
mmol, 5 eq.) and 3-[4-(diphenylphosphino)phenyl]-7-methoxy-
2H-chromen-2-one (PPh2Ar) (50mg, 0.115 mmol, 1 eq.)
in suspension into 5mL of distilled acetone under argon
atmosphere. The gold complex precursor was solubilized after
few minutes. The reaction was maintained at room temperature
for 1.5 h; afterward, 10mL of dichloromethane were added,
and the yellow solution was filtrated through Celite R© and
concentrated under vacuum. The pure product was obtained
after precipitation from a dichloromethane/pentane mixture as
a yellow powder (91mg, 0.092 mmol, 80 % yield).
1H NMR (Acetone-d6, 500.13 MHz, 298K): 3.97 (s, 3H,
OCH3), 4.49 (d, 1H,
2JH−H = 15.6Hz, CH2−PyrBz), 5.05 (d, 1H,
2JH−H = 15.6Hz, CH2−PyrBz), 6.52 (dt, 1H,
3JH−H = 8.5Hz,
4JH−H = 1.5Hz, H
5′ ), 6.88 (dd, 1H, 3JH−H = 7.5Hz,
4JH−H = 3.0Hz, H
6′ ), 6.98 (d, 1H, 4JH−H = 2.5Hz, H
D),
7.00 (dd, 3JH−H = 8.5Hz,
4JH−H = 2.5Hz, H
C), 7.03 (dt,
3JH−H = 8.5Hz,
4JH−H = 0.5Hz, H
4′ ), 7.33 (dd, 1H,
3JH−H = 8.5Hz,
4JH−H = 1.5Hz, H
3′ ), 7.60–7.66 (m, 4H,
Hortho−Ph), 7.70 (d,
3JH−H = 8.5Hz, H
B), 7.73–7.79 (m, 2H,
Hortho−pC6H4), 7.81 (t,
3JH−H = 8.5Hz, H
5), 7.89–8.01 (m, 8H,
Hmeta/para−Ph +Hmeta−pC6H4), 8.06 (d, 1H,
3JH−H = 8.5Hz, H
3),
8.27 (s, 1H, HA), 8.31 (dt, 1H, 3JH−H = 8.5Hz,
4JH−H = 1.5Hz,
H4), 9.25 (broad s, 1H, H6).
13C(1H) NMR (Acetone-d6, 125.77 MHz, 300K): 47.9 (s,
CH2−PyrBz), 56.5 (s, O -CH3), 101.2 (s, CH
D), 113.8 (s,
CHC), 114.0 (s, Cquat−coum), 122.9 (s, Cquat−p−C6H4), 124.0
(d, 1JP−C = 84.3Hz, Cipso−Ph), 124.5 (d,
1JP−C = 83.0Hz,
Cipso−Ph), 124.8 (d,
1JP−C = 70.4Hz, Cipso−p−C6H4), 125.4
(d, 4JP−C = 3.8Hz, CH
5), 127.3 (d, 4JP−C = 3.8Hz, CH
3),
128.8 (s, CH4
′
), 128.9 (d, 4JP−C = 2.5Hz, CH
5′ ),129.8 (s,
CHpara−Ph), 129.9 (s, CH
3′ ), 130.2 (d, 2JP−C = 10.1Hz,
CHortho−Ph), 130.3 (d,
2JP−C = 10.1Hz, CHortho−Ph), 131.0 (s,
CHB), 133.7 (d, 3JP−C = 7.5Hz, CH
6′ ), 134.5 (d, 3JP−C = 2.5Hz,
CHortho−p−C6H4), 134.6 (s + d,
3JP−C = 2.5Hz, Cquat−Bz +
CHortho−p−C6H4), 136.1 (s, CHmeta−Ph), 136.2 (s, CHmeta−Ph
+ CHmeta−p−C6H4), 136.4 (s, CHmeta−p−C6H4), 141.6 (d,
2JP−C = 2.5Hz, C-Au), 143.1 (s, CH
A), 144.2 (s, CH4), 150.8
(s, Cquat−coum), 152.4 (s, CH
6), 156.8 (s, Cquat−pyr), 157.9 (s,
Cquat−coum), 160.4 (s, Cquat−coum), 164.6 (s, Cquat−coum).
31P(1H) NMR (Acetone-d6, 202.45 MHz, 300K): 31.5 (s, 1 P,
PPh3-Coum),−144.2 (h, 1 P, PF6).
ESI-MS (DMSO-MeOH), positive mode exact mass for
[C40H31NO3PAuCl]
+ (836.13901): measuredm/z 836.13656 [M-
PF6]
+.
IR (ATR & FIR, cm−1): 1725, 1613, 1569, 1437, 1362, 1025,
836, 751, 311, 229.
Anal. Calc. for C40H31NO3P2F6AuCl: C, 48.92, H, 3.18, N,
1.43%. Found: C, 48.40, H, 2.70, N, 1.52%.
Photophysical Characterization
UV-Visible absorption spectra were recorded on a JASCO
V630BIO spectrometer. The steady-state fluorescence
emission spectra were obtained by using a JASCO FP8560
spectrofluorimeter instrument. All fluorescence spectra were
corrected for instrument response. The fluorescence quantum
yields (8F) were calculated from equation:
8F
8FR
=
n2
n2R
×
∞∫
0
IF(λE, λF)dλF
∞∫
0
IFR(λE, λF)dλF
×
1− 10−AR(λE)
1− 10−A(λE)
8F and 8FR are fluorescence quantum yields of the compound
and the reference respectively. A(λE) and AR(λE) are the
absorbance at the excitation wavelength, and n is the refractive
index of the medium. IF and IFR are fluorescent intensities
of the compound and the reference respectively. 9,10-
diphenylanthacene (8F = 0.97 in cyclohexane) was used as
standard (Brouwer Albert, 2011). In all 8F determinations,
correction for the solvent refractive index (η) was applied.
Cell Viability Assay
The human breast cancer cell line MCF7, human lung cancer
cell line A549, human colon cancer cell line HCT116 p53
wild-type (+/+) (obtained from the European Centre of Cell
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Cultures ECACC, Salisbury, UK) and a p53 null variant
of HCT116 (–/–) (kindly provided by Dr. G. Hartleben,
University of Groningen), as well as non-cancerous human
embryonic kidney cells HEK-293T (provided by Dr. M. P.
Rigobello, University of Padova, Italy) were cultured in DMEM
(Dulbecco’s Modified Eagle Medium). Human ovarian sensitive
(A2780) and cisplatin resistant (A2780cisR) cells were grown
in Roswell Park Memorial Institute (RPMI) 1,640 medium.
Both media contained GlutaMax supplemented with 10% FBS
and 1% penicillin/streptomycin (all from Invitrogen). Cells
were incubated at 37◦C in a humidified atmosphere of 95%
of air and 5% CO2 in an incubator (Heraeus, Germany).
In the case of the A2780 and A2780cisR cells, the medium
was also supplemented with 2mM L-glutamine. To maintain
resistance, cisplatin-resistant A2780cisR cells were treated with
1µM cisplatin between every third passage.
For evaluation of toxicity, cells were seeded in 96-well plates
(Costar, Integra Biosciences, Cambridge, MA) at a concentration
of 10.000 cells/well (A2780, A2780cisR, MCF-7, HEK-293T) or
6,000 cells/well (HCT116 p53 +/+, HCT116 p53 –/–, A549) and
grown for 24 h in the appropriate medium mentioned above.
Solutions of the compounds were prepared by diluting a freshly
prepared stock solution (10−2 M in DMSO for 1 or 10−3 M in
aqueous solution for cisplatin) of the corresponding compound
in media (RPMI or DMEM for the A2780 or A549, MCF-7,
HCT116 p53+/+, HCT116 p53–/–, and HEK-293T).
Afterwards, 200 µL of these dilutions of the compounds
were added to the wells to obtain a final concentration ranging
from 0 to 120µM, and the cells were incubated for 72 h.
Following 24 or 72 h drug exposure, 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) was added to the
cells at a final concentration of 0.5mg mL−1 and incubated
for 2 h. Then, the culture medium was removed and the violet
formazan (artificial chromogenic precipitate of the reduction of
tetrazolium salts by dehydrogenases and reductases) dissolved in
200 µL DMSO. The optical density of each well (96-well plates)
was quantified in triplicates at 550 nm using a multi-well plate
reader, and the percentage of surviving cells was calculated from
the ratio of absorbance of treated to untreated cells. The EC50 was
calculated as the concentration reducing the proliferation of the
cells by 50% and it is presented as a mean (± SD) of at least three
independent experiments.
Statistics
A minimum of three independent experiments were performed
with the cells, with four replicates for each condition. The
EC50 values were calculated, using GraphPad Prism, as the
concentration reducing the viability of the cells or slices by 50%,
relative to the untreated samples using a nonlinear fitting of
log [compound concentration] vs. response and is presented
as the mean ± SD of at least three independent experiments.
Statistical testing was performed with two-way ANOVA with
each individual experiment as random effect. In all graphs and
tables the mean values and standard deviation (SD) are shown.
ICP-MS Studies
The concentrations of platinum, gold and copper were
measured by inductively coupled plasma mass spectrometry
(ICP-MS) using an Elan 6,000 spectrometer (Perkin Elmer Sciex,
Concord, ON, Canada) and Micromist Nebulizer and a cyclonic
spraychamber (Glas Expansion Pocasset, MA, U.S.). Nebulizer
gas, lens voltage and RF power were optimized daily using a
10 µg/L Pt standard in 0.1% (V/V) HCl and 0.65% (V) HNO3,
normal settings were: Rf power 1,350W, nebuliser gas flow rate
0.95 L min−1, and lens voltgate 10V. Acquisition parameters
were 50ms dwell time, 1 sweeps reading, 5 replicates and 25
readings per replicate, monitoring all or a subset of 195Pt+,
196Pt+, 197Au+, and 63Cu+. The instrument was tuned at the
beginning of each analysis to ensure optimal operation.
Samples were dried by vacuum centrifugation (Eppendorf,
concentrator plus) at 60◦C for 2 h. Cell samples were digested
using 200 µL 65% HNO3 and 50 µL 30% H2O2 overnight until
the solution was clear. Samples were prepared for analysis by
dilution to 5mL with 0.65% (V/V) HNO3 and 0.1% (V/V) HCl.
The external standards were prepared from a 10 mg/L Au and
Pt stock solution (CPI International, Peak Performance, 4400-
120213WG01, Lot# 12B214) or Cu stock solution (Plasma CAL,
SCL SCIENCE, Q.C. no 4, Cat# 140-102-045, Lot SC5322198)
with 0.65% (V/V) HNO3 and 0.1% (V/V) HCl. All reagents were
of the highest available purity.
Metal Content Determination After 24/72h
+/– Inhibitor
A2780 or A2780cisR cells were plated into 25 cm2 culture flasks
(CellStar, Grenier Bio, Germany) with RPMI 1640 medium up
to a volume of 5mL per flask. After 24 h, the cells were treated
with a mixture of 15 or 20µM cisplatin for 24 h, or 5 or 10µM
cisplatin for 72 h, +/– cimetidine or +/– CuCl2. Cimetidine
was used at 300µM concentration in H2O, and CuCl2 was
used at 30µM in H2O, both non-toxic to cancer cells. The
same set-up was used for compound 1, but the compound was
incubated at 5 or 10µM for 24 h, and 3 or 6µM for 72 h,
respectively. After 24 or 72 h, the medium was removed, and
the cells were washed two times with 3mL ice-cold PBS to
remove dead cells. Thus, lysis buffer (500 µL) was added and
the samples were stored on ice for 20min. Afterwards, cells were
detached by using a scrubber policemen and the cell suspension
was transferred to a 1.5mL Eppendorf tube. 200 µL of the
sample were transferred to a new Eppendorf tube for ICP-MS
analysis, while 5 µL of cell suspension was used for protein
determination.
Metal Content Determination During
120min Incubation +/– Inhibitor
A2780 or A2780cisR cells were plated into 25 cm2 culture flasks
(CellStar, Grenier Bio, Germany) with RPMI 1,640 medium up
to a volume of 5mL per flask. The next day, the cells were treated
with 5µM cisplatin or with 3µM compound 1 (+/– cimetidine
or +/– CuCl2) for 10
′, 20′, 30′, 60′ ,and 120′ min. The samples
were processed as described above.
Protein Assay
Protein determination was performed using BioRad DCTM
Protein Assay reagents A, B, and S (Bio-Rad). Using a 96-well-
plate, 5 µL of standard (0, 5, 10, 15, 20, 25, and 30 mg/ml bovine
serum albumin) and samples were analyzed in duplicate. First,
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25.5 µL reagent-mix A+S (25 µL A + 0.5 µL S) was added and
then 200 µL reagent B. The absorbance at 610 nm was measured
after 15min (stored in dark) using a PlateReader (Perkin Elmer,
EnVision, 2104 Multilabel Reader).
Fluorescence Microscopy
A2780 cells were seeded (5 × 105 for each sample) and
grown on 8 well microscope plates, coated with Poly-L-lysine
hydrobromide (Sigma-Aldrich, P6516) with RPMI medium.
After 24 h, cells were incubated with various concentrations
of Au(III) compound 1 in RPMI, without FCS for 1 h at
37◦C. Afterwards, cells were rapidly washed with cold PBS
and then fixed with 2% paraformaldehyde for 30min at 4◦C.
For visualization of the nuclei with PI (propidium iodide),
cells were permeabilized with 0.2% Triton X-100 for 20min
at 4◦C and treated with 1 µg/µl of PI for 10min at room
temperature. Cells were washed once with PBS and then analyzed
by confocal microscopy. As preparation for visualization, the
plate wells were removed from the slide and glycerol was used
to cover the slide with a glass cover slip. The fluorescence
was analyzed using a Leica DM4000 B Automated Upright
Microscope, equipped with the appropriate filters. PI was excited
at 547 nm (emission wavelength 572 nm) and compound 1 at
358 nm (emission wavelength 461 nm, DAPI filter). The acquired
images were obtained using the individual filters and a combined
image, overlaying the fluorescence was acquired using the Leica
microscope software.
RESULTS
Synthesis and Characterization
A novel cyclometallated Au(III) compound 1 was synthesized
adapting already established procedures for similar complexes
(Figure 2).(Bertrand et al., 2015) In details, the C∧N precursor
[Au(pyb-H)Cl2] (Cinellu et al., 1995) was reacted with the
phosphine 3-[4-(diphenylphosphino)phenyl]-7-methoxy-2H-
chromen-2-one (PPh2Arcoum) (Hanthorn et al., 2012) to
yield the fluorescent Au(III) compound 1. The complexation
of the phosphine ligand with [Au(pyb-H)Cl2] as well as the
isomeric purity of compound 1 was analyzed by 31P(1H) NMR
spectroscopy. The NMR spectrum (Figure S1a) shows a singlet
at 31.5 ppm of the coordinated phosphorous shifted downfield
by 35 ppm with respect to the corresponding precursor
(Figure S1b) (Bertrand et al., 2015). The 1H NMR spectrum
of 1 (Figure S2a) shows a downfield shift of the signal of the
pyridine proton in position 6 by 0.05 ppm associated with a
morphological change of the pyridine moiety. A splitting of the
signals corresponding to the carbons of the two phenyl rings
compared to the free ligand (Figure S2b) was observed due
to their diastereotopic feature induced by the fixed geometry
of the cyclometallated ligand as depicted in Figure S2c in the
Supplementary Material. The same splitting of the signals of
the two phenyl rings was observed in the 13C(1H) spectrum of 1
(Figure S3). Moreover, another splitting of the signal due to the
coupling of the phosphorous atom with carbons and hydrogens
is observed. Compound 1 in dichloromethane exhibits a typical
absorption band at 361 nm and a fluorescence emission band of
the coumarin chromophore at 429 nm (Figure S4). As previously
observed, the complexation induces a bathochromic shift of the
absorption wavelength with respect to free phosphine ligand (+
33 nm), while there is no significant modification of emission
wavelength (Dondaine et al., 2016). It is worth noting that
complexation of gold(III) preserves the smart character of the
coumarin-phosphine ligand that we highlighted for gold(I)
complexes (Ali et al., 2015; Dondaine et al., 2016). Indeed,
compound 1 displayed a quantum yield of fluorescence almost
8-fold higher than the free phosphine (38 and 5% respectively).
This phenomenon will make possible to check the stability of
the P-Au bond by microscopy of fluorescence experiment in
vitro: if the bond breaks, the fluorescence emission will drop
dramatically (Figure S5).
Antiproliferative Effects
The antiproliferative effects of the gold(III) compound 1 were
studied in different human cancer cell lines in comparison
to cisplatin, via a classical 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) assay after 72 h incubation
(see experimental for details). Specifically, the selected human
cancer cell lines were A2780 and A2780cisR (ovarian carcinoma
cisplatin sensitive and resistant, respectively), MCF7 (breast
carcinoma), A549 (lung carcinoma) as well as against HCT116
p53 +/+ and –/– (colon carcinoma p53 expressing and knock-
out, respectively). The tumor protein p53 is a tumor suppressor
gene and known to be downregulated in cisplatin resistant cancer
tissues (Li et al., 2007).
The obtained EC50 values are summarized in Table 1. Overall,
compound 1 exhibits a moderate toxicity profile in all tested
cell lines in line with previous studies on similar C∧N gold(III)
complexes, while being more effective against the ovarian A2780
cancer cells (Bertrand et al., 2015). Compared to cisplatin, 1
shows a moderately higher toxic effect against A2780cisR, which
suggests that different mechanisms of anticancer activity with
respect to the Pt(II) agent may be in place, as well as possible
alternative transport and accumulation pathways in this cell line.
Instead, no statistically significant difference of EC50 values was
observed in the HCT116 p53 –/– cells among the two drugs.
This is different from what has been observed for other families
of organometallic Au(I) complexes featuring N-heterocyclic
carbene ligands (Estrada-Ortiz et al., 2017). Moreover, similar
toxicity with respect to cisplatin was detected in the case of the
non-cancerous HEK-293T cells. In addition, we also evaluated
the Imax, calculated as the survival rates at maximum inhibition,
which provide a measure of drug maximal toxicity, while the
EC50 values reflect the drug potency. As it can be seen from the
Imax values reported inTable 1, compound 1 shows similar effects
as cisplatin, made exception for the HCT116 p53 –/–, MCF7 and
A549 cell lines, where the Pt(II) drug has a higher Imax.
Due to the highest activity against the ovarian cancer cells,
both sensitive and resistant to cisplatin, these cells were selected
for further experiments to investigate the transport mechanisms
for the gold(III) compound 1 in comparison to cisplatin.
Both A2780 and A2780cisR cells were recently evaluated from
Sørensen et al. (2016) for the expression levels of CTR1, OCT2,
and ATP7A/B transporters. Notably, the cisplatin resistant
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TABLE 1 | Antiproliferative effects of gold(III) compound 1 (expressed as EC50 and Imax values) compared to cisplatin against different human cancer cell lines and
non-tumorigenic HEK-293Tcells, after 72 h incubation.
EC50 (µM)
a [Imax(%)]
Compound A2780 A2780cisR HCT116
p53 +/+
HCT116
p53 –/–
MCF7 A549 HEK-293T
1 2.4±0.3
[0.044]
11 ± 0.5
[0.054]
9.8 ± 0.9
[0.058]
18.4±1.1
[0.072]
12 ± 3
[0.03]
26± 5
[0.041]
10 ± 3
[0.030]
Cisplatin 2.3±0.5
[0.065]
30 ± 1
[0.073]
5.3 ± 0.2
[0.056]
22.9±2.3
[0.185]
20 ± 3
[0.124]
12±1
[0.105]
8.6±1.3
[0.030]
aData are expressed as mean ± SD (n ≥ 3).
A2780cisR cells show a significantly higher expression of the
copper eﬄux transporters ATP7A (1.3-fold) and ATP7B (5-
fold) as well as of the cation uptake transporter OCT2 (1.3-
fold). The copper uptake transporter CTR1 is on the other hand
less expressed in A2780cisR cells compared to the A2780 (0.4-
fold). These data suggest that the resistance observed in the
A2780cisR cells is at least partly caused by a different balance
between uptake and eﬄux of cisplatin resulting from a decreased
influx via CTR1 and concomitant increased eﬄux of cisplatin by
ATP7A/B, thereby decreasing the intracellular exposure of the
cells to cisplatin.
Studies on the Mechanisms of Transport
Competition Experiments
The antiproliferative effects of compound 1 and cisplatin were
determined after 24 and 72 h incubation in order to observe
the development of the toxicity over time (Table 2). Overall,
compound 1 is more potent in the A2780 cells, than in the
resistant A2780cisR cells at both incubation times. In addition,
after 24 h incubation, compound 1 is 5-fold more active than
cisplatin in A2780 cells, and 7-fold more active in A2780cisR
cells. However, after 72 h incubation, both compounds display
the same cytoxicity in A2780, while the gold(III) compound
is still ca. 3-fold more active in A2780cisR than cisplatin. In
addition, there is no significant difference between the EC50
values at either 24 or 72 h treatment of A2780cisR cells with
compound 1. Instead, in A2780 cells, the gold(III) compound
shows a 2-fold decrease of the EC50 values from 24 to
72 h incubation, indicating increase of activity during chronic
exposure.
In order to evaluate the involvement of OCT2 and CTR1
uptake transporters in the metallodrugs accumulation, the
compounds’ antiproliferative effects were further tested in the
presence of transporter inhibitors or competitor substrates,
respectively (see experimental section for details). If these
transporters are involved in the drug uptake, their inhibition
should lead to a reduced intracellular accumulation of the
metal complexes and to a decrease in cytotoxic effects,
and thus, an increase in EC50 values. Conversely, inhibiting
possible eﬄux transporters such as MATE and ATP7A/B
should lead to metallodrug accumulation and enhancement
of its antiproliferative effects. Cimetidine (300µM, Cim)
was selected as inhibitor for OCTs and MATE, and CuCl2
TABLE 2 | EC50 values of compound 1 and cisplatin against A2780 and
A2780cisR cells, incubated in absence and presence of CuCl2 or cimetidine
(Cim), recorded after 24 and 72 h incubation.
EC50 (µM)
a
24h 72h
Compound A2780 A2780cisR A2780 A2780cisR
1 5.8 ± 1.5 15 ± 4 2.4 ± 0.3 11 ± 0.5
1 + Cim 6.6 ± 0.3 18.2 ± 6.1 0.7 ± 0.2** 8.1 ± 0.5*
1 + CuCl2 4.1 ± 0.3 6.1 ± 1.9* 0.2 ± 0.1** 3.1 ± 1.0**
Cisplatin 26 ± 2 103 ± 3 2.3 ± 0.5 30 ± 1
Cisplatin + Cim 22.0 ± 2.1 91.7 ± 4.2 1.0 ± 0.1** 21.3 ± 1.1**
Cisplatin+ CuCl2 22.2 ± 1.3 51.0 ± 4.9** 0.5 ± 0.2** 18.0 ± 0.6**
aData are expressed as mean ± SD (n ≥ 3).
The reported values are the mean ± SD of three independent experiments. For statistical
analysis, the two way ANOVA was used. *p ≤ 0.05, **p ≤ 0.01 indicate the difference is
significant when compared to samples treated with the metallodrugs only (control).
(30µM) as competitive substrate of both CTR1 and ATP7A/B
(Spreckelmeyer et al., 2014). Experiments were performed in
A2780 and A2780cisR cells after 24 and 72 h incubation with the
compounds. It should be noted that CuCl2 and cimetidine do not
show any anticancer effect on A2780 or A2780cisR cell lines at the
selected concentrations (data not shown). The obtained results
are summarized in Table 2 and in Figures S6, S7.
After 24 h incubation, neither cimetidine nor CuCl2 showed
an effect on the potency of gold(III) compound 1 or cisplatin
in A2780 cells (Figure S6A). However, in A2780cisR cells
(Figure S6B), both cisplatin and compound 1 had a significantly
increased activity when co-incubated with CuCl2. For cisplatin
the resistance was only partly reduced, but for gold(III)
compound 1 the resistance was fully compensated resulting in
a similar toxicity in both cell lines. These results support the
hypothesis that CuCl2 may interfere with the metallodrugs de-
toxification mechanisms involving the copper eﬄux transporters
(ATP7A/B), which are expressed at much higher levels in the
A2780cisR cells than in the wild type A2780 cells (Sørensen
et al., 2016). Apparently, these eﬄux transporters play a minor
role in the wild type A2780 cells. Furthermore, the lack of effect
of cimetidine on the efficacy of both cisplatin or compound 1
(Figure S6A) in both cell lines might indicate that drug uptake
processes by OCTs and eﬄux by MATE are not relevant.
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After 72 h incubation of the A2780 cells, both cimetidine and
CuCl2 increased the potency of compound 1 significantly, 3.5-
fold and 12-fold, respectively. For cisplatin, a 2.5-fold and 4.5-
fold increased toxicity could also be observed with cimetidine and
CuCl2, respectively (Figure S7A). The same effect was observed
in A2780cisR cells, but to a lower extent (Figure S7B). This
discrepancy may be rationalized by the hypothesis that for both
compounds, at 72 h incubation, eﬄux mechanisms are inhibited
by CuCl2 and cimetidine, possibly via inhibition of ATP7A/B
and MATE, respectively. However, it should be noted that in
conditions of chronic drug exposure other pathways may cause
the observed increased cytotoxic effects other than transport
mechanisms.
Metal Accumulation Studies by ICP-MS
After evaluating the toxic effects of both compounds in
cancer cells in the presence and absence of transport
inhibitors/competitors, the metal content (Au or Pt) was
determined by inductively coupled plasma mass spectrometry
(ICP-MS) to gain further insights into the drug accumulation
mechanisms. For these experiments two concentrations of the
metal compounds were chosen based on their EC50 values at
the selected incubation time (24 or 72 h), namely EC50 or 2-fold
EC50 concentrations against the A2780 cells were considered for
the two drugs. The obtained results are reported in Table 3 and
expressed in ng metal/µg protein.
Au Accumulation in Cancer Cells
When cells were treated with compound 1, as expected, the
metal content increased as a function of concentration (Table 3,
Figure 3, Figure S8). Interestingly, no significant differences in
Au content could be observed between the two cell lines (sensitive
or resistant to cisplatin) treated with the same concentrations of
the gold(III) compound 1 at either incubation times. Considering
the above mentioned marked differences in EC50 values for 1
between the two cell lines and the different incubation times
(Table 2), the differences in accumulation mechanisms may not
play a major role in determining the overall antiproliferative
effects of the gold(III) complex.
When cells were co-treated for 24 h with the gold compound
and CuCl2, increased accumulation of Au was observed in both
cell lines treated with 10µM concentration of compound 1
(Table 3, Figure 3). The effect of the CuCl2 co-incubation was
most marked in the A2780 cells with a 4-fold increase in Au
content compared to the controls, whereas the metal content
increased only of 2-fold in the A2780cisR. A 2-fold increase
was observed at 5µM in both cell lines, but this increase was
not statistically significant. Overall, these results are in line with
the enhanced effect of the copper/drug co-incubation on the
observed antiproliferative effects (Table 2).
Co-incubation of the gold(III) compound for 24 h with
300µM cimetidine resulted in a slightly increased accumulation
of Au only in the A2780 wild type cells at 10µM of compound
1, but not at 5µM, and no effect was seen in the A2780cisR cells
(Figure 3) in line with the antiproliferative activity data (Table 2).
The same type of experiments was repeated after 72 h
treatment of cells with compound 1 at either 3 or 6µM.
After 72 h incubation in the presence of CuCl2, a ca. 2-fold
TABLE 3 | Metal content determination by ICP-MS after exposure of A2780 and
A2780cisR cells with compound 1 and cisplatin, incubated in absence and
presence of CuCl2 (30µM) or cimetidine (Cim, 300µM), recorded after 24 and
72 h incubation.
Au and Pt content [ng metal/µg protein]
24h 72h
Treatment A2780 A2780cisR A2780 A2780cisR
COMPOUND 1
[5µM] 0.04 ± 0.01 0.04 ± 0.01 nd nd
[10µM] 0.12 ± 0.03 0.10 ± 0.02 nd nd
[5µM] + CuCl2 0.08 ± 0.02 0.08 ± 0.01 nd nd
[10µM] + CuCl2 0.48 ± 0.06 0.21 ± 0.01 nd nd
[5µM] + Cim 0.04 ± 0.01 0.04 ± 0.01 nd nd
[10µM] + Cim 0.26 ± 0.06 0.12 ± 0.02 nd nd
[3µM] nd nd 0.08 ± 0.01 0.05 ± 0.01
[6µM] nd nd 0.19 ± 0.02 0.15 ± 0.01
[3µM] + CuCl2 nd nd 0.16 ± 0.03 0.12 ± 0.01
[6µM] + CuCl2 nd nd 0.15 ± 0.01 0.28 ± 0.03
[3µM] + Cim nd nd 0.09 ± 0.02 0.06 ± 0.02
[6µM] + Cim nd nd 0.25 ± 0.05 0.16 ± 0.01
[15µM] 0.07 ± 0.01 0.06 ± 0.01 nd nd
[20µM] 0.17 ± 0.04 0.08 ± 0.02 nd nd
[15µM] + CuCl2 0.09 ± 0.01 0.07 ± 0.01 nd nd
[20µM] + CuCl2 0.20 ± 0.03 0.13 ± 0.01 nd nd
[15µM] + Cim 0.08 ± 0.02 0.06 ± 0.01 nd nd
[20µM] + Cim 0.25 ± 0.02 0.10 ± 0.01 nd nd
[5µM] nd nd 0.04 ± 0.02 0.02 ± 0.01
[10µM] nd nd 0.07 ± 0.02 0.05 ± 0.01
[5µM] + CuCl2 nd nd 0.05 ± 0.02 0.02 ± 0.01
[10µM] + CuCl2 nd nd 0.09 ± 0.02 0.07 ± 0.01
[5µM] + Cim nd nd 0.02 ± 0.01 0.01 ± 0.01
[10µM] + Cim nd nd 0.05 ± 0.02 0.04 ± 0.01
The reported values are the mean ± SD of three independent determinations. nd, not
determined.
increase in Au content was observed both in A2780 cells and
in A2780cisR cells at either metallodrug concentrations, except
for the co-incubation of 6µM 1 in the cisplatin sensitive cells,
where no difference was observed with respect to controls
(Table 3, Figure S8). This may be explained by the fact that
after 72 h, 6µM is about 2-fold the EC50 value for 1 in A2780
cells, which may have caused extensive cell death, altering
membrane integrity and Au leakage from the cells. Concerning
the cimetidine treatment, this did not have any significant effect
on the Au content of the cells after 72 h of incubation (Table 3,
Figure S8).
Pt Accumulation in Cancer Cells
Afterwards, the Pt content was evaluated in A2780 and
A2780cisR cells treated with cisplatin after 24 (Table 3, Figure 3)
or 72 h incubation (Table 3, Figure S9) by ICP-MS. At 24 h, the
Pt content was the same for both cell lines, despite the known
differences in the expression of hCTR1 and OCT transporters
(Sørensen et al., 2016). The increase in metal content was
concentration dependent over 24 h in the A2780 cells, while a
similar trend could not be observed in the cisplatin resistant
cells, where the Pt content remained substantially unaltered
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FIGURE 3 | Au content after 24 h incubation of (A) A2780 (B) A2780cisR cells treated with 5µM (black) and 10µM (gray) of compound 1. Pt content after 24 h
incubation of (C) A2780 and (D) A2780cisR with 15µM (black) and 20µM (gray) cisplatin. Data are expressed as mean ± SD (n = 3).
at both drug concentrations and incubation times (Figure 3,
Figure S9). This concentration dependent effect could not be
observed in the case of the A2780cisR cells also after 72 h
incubation, supporting the idea that higher detoxification and
possibly eﬄux mechanisms may be in place. Notably, no
significant difference in Pt content could be observed after
co-incubation with either cimetidine or CuCl2. Thus, these
data cannot explain the observed increase in anticancer effects
(Table 2).
Copper Accumulation in Cancer Cells
The viability results of cisplatin treated human ovarian cancer
cells showed a decreased EC50 value after co-incubation with
CuCl2. However, the ICP-MS data did not show an increased
Pt content that could be responsible for such an effect. In
order to reinforce the evidence that inhibition of the copper
transporters by cisplatin or by the Au(III) complex is not
relevant to their mechanism of anticancer effects, we investigated
whether the Cu2+ content was increased due to the co-
incubation with each metallodrug. Concerning copper uptake,
CTR1 affinity to Cu is between 0.6µM in fibroblasts and
13µM in murine hepatocytes, (Lee et al., 2002) while ATP7B
binding affinity to Cu is 2.5 ∗ 10−17 M (Hilário-Souza et al.,
2011). Both transporters are not only selective for Cu, but
also for example for Ag(I), Cd(II) and Fe(III) (Liang et al.,
2014).
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FIGURE 4 | Evaluation of copper content in human ovarian cancer cells
treated with 1. Cu content in A2780 (WT) and A2780cisR (Res) cells after
(A) 24 h and (B) 72 h incubation with 30µM CuCl2 and different
concentrations of compound 1. Data are expressed as mean ± SD (n = 3).
Initially, copper content was evaluated in both the wild-
type A2780 and cisplatin resistant A2780cisR cells by ICP-
MS since the different CTR1/ATP7A/B transporter expression
levels(Sørensen et al., 2016) may have an effect in its
accumulation. The obtained results show that both cell lines have
the same basal copper content (0.056 ± 0.02 ng Cu in A2780
and 0.045 ± 0.01 ng Cu in A2780cisR). Furthermore, treatment
with CuCl2 (30µM) did not significantly alter these basal levels
(Figure 4).
Concerning metallodrug treated cells, it could be observed
that the copper content did not decrease in the cell lines upon
treatment with the Au(III) compound 1 for 24 (5 and 10µM)
and 72 h (3 and 6µM), at any selected drug concentration
(Figure 4). Instead, co-incubation of 1 with CuCl2 induced an
increased copper accumulation compared to controls after 24 h
in both cell lines. At 72 h, the Cu content was markedly increased
mainly in the A2780 cells. Overall, the ICP-MS data showed an
increased Au and Cu content after 24 and 72 h incubation in
the CuCl2 co-incubation experiments, which may be responsible
for the observed increased antiproliferative effects in the same
cells (Table 3). The effect of the increased Cu-content is not fully
understood yet, but an additive or even synergic anticancer effect
with Au may be possible.
Considering cisplatin treatment, no significant difference in
the Cu content between the controls and cisplatin treated cells
could be observed in both cell lines after 24 and 72 h incubation
(Figure 5). Instead, after 24 h, the Cu content significantly
increases at both concentrations of cisplatin co-incubated with
CuCl2 in both cell lines. However, this effect was absent in the
A2780cisR cells incubated for 72 h. The ICP-MS data showed no
increased Pt and Cu content after 24 h and 72 h incubation in the
CuCl2 co-incubation experiments (Table 3).
To summarize the results concerning the gold(III) complex,
the following can be concluded: after 24 h, co-incubation of 1
with CuCl2, but not with cimetidine, induced a significantly
higher antiproliferative effects in A2780cisR cells, whereas in
A2780 cells no effect was seen of either CuCl2 or cimetidine.
After 72 h incubation, co-incubation of 1 with CuCl2 resulted in
an increase in cytotoxicity and increase in Au and Cu content in
both cell lines as demonstrated by ICP-MS. Based on these results
two explanations can be suggested for these effects: (i) compound
1 is a substrate for ATP7A/B, and inhibition of the eﬄux
transporter ATP7A/B by excess CuCl2 results in a higher Au
accumulation and higher drug potency, and/or (ii) the increased
overall cytotoxicity is a result of additive or synergistic effects
of Au and Cu accumulation via different transport mechanisms.
Furthermore, a direct involvement of the CTR1 or OCT2 in
the uptake of the gold drug, as well as of MATE in its eﬄux,
could not be supported based on our studies. The increased
efficacy of compound 1 in the presence of cimetidine after 72 h of
incubation in A2780 cells, but not after 24 h, is difficult to explain,
as no concomitant increased accumulation of Au was observed
by ICP-MS. Studies with other, more selective, inhibitors for each
single drug transporter are needed to confirm these results.
Concerning cisplatin, similarly to compound 1, 24 h drug
incubation with CuCl2 shows a significant decrease in viability
in A2780cisR cells, although not as strong as for the gold(III)
compound 1. After 72 h, co-incubation of cisplatin with either
cimetidine or CuCl2 leads to an increase in cytotoxicity, but no
increase in Pt content could be observed in both cell lines as
demonstrated by ICP-MS. This result, together with the evidence
for increased Cu content in A2780 cells, leads to the hypothesis
that copper accumulation is the reason for the observed enhanced
anticancer effects in this cell line.
Metal Uptake Studies
In order to specifically evaluate uptake mechanisms of
metallodrugs in cancer cells, we measured the metal content (Au,
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FIGURE 5 | Evaluation of copper content in human ovarian cancer cells
treated with cisplatin. Cu content in A2780 (WT) and A2780cisR (Res) cells
after (A) 24 h and (B) 72 h incubation with 30µM CuCl2 and different
concentrations of cisplatin. Data are expressed as mean ± SD (n = 3).
Pt) in both A2780 and A2780cisR at different time points during
the first 120min of incubation in cells by ICP-MS. Thus, samples
were taken after 10, 20, 30, 60, and 120min and the obtained
results are reported in (Figures 6, 7).
In the case of compound 1, co-treatment with cimetidine
did not affect the Au uptake in both cell lines at any recorded
concentration. When cells were co-incubated with CuCl2, a
significantly higher Au content could be observed only after
120min in the A2780 cells (Figure 6A), but not in the cisplatin
resistant ones (Figure 6B). Overall, both cimetidine and CuCl2
do not change the uptake of compound 1. It should be noted
that, between 10 and 20min incubation, a drop in Au content
can be observed in A2780 cells. We do not have an explanation
for that thus far, but it should be further investigated in additional
experiments.
In the case of cisplatin, the Pt content in cells co-incubated
with cimetidine or CuCl2 did not show any difference over
120min in both cell lines (Figure 7). A similar trend was
observed in the co-treatment with cimetidine, made exception
for the significantly increased Pt content recorded at 120min in
A2780 cells. Considering the whole set of data, it is also worth
noting that metal accumulation is more efficient in the case of the
gold(III) compound 1 compared to cisplatin in both cancer cell
lines over time (see summary of the obtained data in Table 3).
In line with the aforementioned accumulation studies, a
direct involvement of OCTs or CTR1 in the uptake of cisplatin
was not observed. Otherwise, inhibition by cimetidine should
have resulted in lower cytotoxicity and lower Pt, accumulation
in the cells, which instead was not recorded. It should be
also considered that Holzer and Howell showed that, as a
consequence of cisplatin and copper incubation, the CTR1
transporter undergoes rapid down-regulation in human ovarian
2008 cancer cells, and that it might be internalized from the
membrane, potentially leading to a decreased cisplatin uptake
(Holzer and Howell, 2006). However, a decreased Pt uptake
was also never evidenced in our results. Similarly, a direct
involvement of MATE or ATP7A/B in the accumulation of
cisplatin could not be confirmed.
Fluorescence Microscopy Studies
To investigate the sub-cellular localization of the Au complex,
we performed fluorescence microscopy experiments on A2780
cells treated with Au(III) compound 1 and the two inhibitors
cimetidine and CuCl2. Propidium iodide (PI) staining was used
to evidence cell nuclei. The pictures show the A2780 cells
after 2 h incubation with gold(III) compound 1 (2-fold the
EC50) (Figure 8). The strong fluorescence observed indicates
that the coumarin-phosphine ligand is still coordinated to
gold(III) cation. The compound itself does not co-localize
with PI in the nuclei, but clearly enters the cells and is
localized in organelles in the cytoplasm. For example, a similar
distribution pattern was observed for a gold(I) complex featuring
the same coumarin ligand as 1 (Ali et al., 2015). In this
case, the gold(I) complex was hypothesized to accumulate
in lipid rafts, cellular domains containing plasma membrane
proteins and lipids, which are involved in the regulation
of numerous cell functions, including signaling, trafficking,
migration, adhesion, and growth. This observation points toward
a different mechanism of action compared to cisplatin and
suggests that the DNA damage may not play a pivotal role
in the toxicity of the Au compound. Co-incubation with
either cimetidine or CuCl2 did not change the intracellular
accumulation pattern (Figure 8).
CONCLUSIONS
In the past years, several studies have been carried out to
elucidate the mechanisms of uptake and eﬄux of cisplatin in
cancer cells and kidney slices, as well as in numerous in vitro
models of cancer cells (Spreckelmeyer et al., 2014). Despite
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FIGURE 6 | Gold uptake determination in cancer cells–Au content [ng metal/µg protein] in A2780 (A) and A2780cisR cells (B) treated with 1 and co-treatment with
cimetidine or CuCl2. Data are expressed as mean ± SD (n = 3).
FIGURE 7 | Platinum uptake determination in cancer cells–Pt content [ng metal/µg protein] in A2780 (A) and A2780cisR cells (B) treated with cisplatin and
co-treatment with cimetidine or CuCl2. Data are expressed as mean ± SD (n = 3).
the numerous research efforts, such transport mechanisms
are not yet fully understood. In addition, the mechanisms
leading to activity/toxicity and cellular accumulation of new
experimental anticancer gold complexes have received scarce
attention, albeit the numerous compounds’ structures published
in the literature. Recently, we have reported on a promising
family of gold(III) C∧N complexes as cytotoxic agents,
with [Au(pyb-H)PTACl] (pyb-H= C∧N cyclometallated 2-
benzylpyridine)(Bertrand et al., 2015) (Figure 1) as one of the
most effective derivatives in cancer cells in vitro. In order
to broaden the scope of our work and develop a compound
trackable in cells via fluorescence microscopy, we report here on
the cytotoxic effects of a new fluorescent gold(III) C∧N complex
1 studied in a panel of human cancer cell lines in comparison
to cisplatin in vitro. The results show that 1 is more active than
cisplatin in a number of cell lines, including MCF7, HCT16 p53
–/–, and A2780cisR cells. However, it has similar antiproliferative
effects for other cancer cells, including the ovarian A2780
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FIGURE 8 | Fluorescence microscopy of A2780 cells treated for 2 h with compound 1 (5µM) with/without 300µM cimetidine or with/without 30µM CuCl2.
cells. The compound is also moderately cytotoxic toward the
non-tumorigenic HEK cells. Additionally, we evaluated for
the first time the involvement of different uptake and eﬄux
transporters—namely OCTs, CTR1, MATEs, and ATP7A/B—
in the accumulation mechanisms of 1 in human ovarian
cancer cells in vitro, using competitive inhibitors/substrates and
determining the intracellular metal content by ICP-MS. The
results are compared with those obtained for cisplatin in the same
experiments.
The uptake and intracellular accumulation of the gold(III)
compound 1 is more efficient than that of cisplatin, as
judged from the metal content assessed in both A2780
and A2780cisR cells by ICP-MS. In general, while uptake
transporter OCT2 and CTR1 are unlikely to be involved
in the transport mechanisms of both compounds in the
selected cell lines, as well as in their antiproliferative effects,
the eﬄux transporters ATP7A/B should be investigated
further in the case of the gold complex. The preliminary
fluorescencemicroscopy studies indicate that the gold compound
accumulates intracellularly mainly in cytoplasmic organelles
other than nuclei. Further studies are necessary to establish
if these corresponds to mitochondria or lysosomes among
others.
Overall, these initial results may constitute the basis
for future more extensive studies on experimental
metallodrugs transports and their relevance to the mechanism
of activity/resistance toward different types of cancer,
highlighting the differences with classical platinum-based
chemotherapeutics.
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